肝胆相照论坛

标题: Aligos Therapeutics将在AASLD2019期间展示多张海报 张贴海 [打印本页]

作者: StephenW    时间: 2019-10-30 17:20     标题: Aligos Therapeutics将在AASLD2019期间展示多张海报 张贴海

Aligos Therapeutics to Present Multiple Posters During The Liver Meeting® 2019
Posters to highlight recent advances for the company’s development-stage products for HBV and NASH

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a pre-clinical stage biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC), today announced the upcoming presentation of four abstracts at The Liver Meeting® hosted annually by the American Association for the Study of Liver Disease (AASLD). The 2019 meeting will be held in Boston on November 8-12.

Experts from Aligos’ team of scientists will present posters detailing recent advances in the company’s products in development to address CHB and NASH. Poster presentation details include the following:

Poster session I
Date/Time: Friday, November 8, 12:30 p.m. – 1:30 p.m. ET
Location: John B. Hynes Memorial Convention Center

    Poster Title: S-Antigen Transport-inhibiting Oligonucleotide Polymers (STOPs) can Effectively Inhibit Hepatitis B Surface Antigen (HBsAg) Secretion from Hepatitis B Virus (HBV) Cell Lines
    Poster number: 689
    Presenter: Jin Hong (Director, Oligonucleotide Biology)

    Poster Title: Preclinical Assessment of a Novel Capsid Assembly Modulator, ALG-001075, Demonstrates Best-in-Class In Vitro Potency and In Vivo Antiviral Efficacy
    Poster number: 699
    Presenter: Yannick Debing (Senior Scientist)

    Poster Title: Preclinical Assessment of Potency and Efficacy of a Novel Class-II Capsid Assembly Modulator ALG-001024
    Poster number: 703
    Presenter: Andreas Jekle (Director, Virology)

Poster session IV
Date/Time: Monday, November 11, 12:30 p.m. – 1:30 p.m. ET
Location: John B. Hynes Memorial Convention Center

    Poster Title: Preclinical development of ALG-009 as a Potent and Selective Thyroid Hormone Receptor Beta Agonist for the Treatment of NASH
    Poster number: 2149
    Presenter: Jerome Deval (Director, Biochemistry)

About Aligos
Aligos Therapeutics, Inc. is a privately held biotechnology company that was founded in 2018 with the mission to become a world leader in the treatment of liver diseases. Aligos is focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC), which collectively affect hundreds of millions of people across the world. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of best-in-class molecules.
Please visit www.aligos.com for more information.
作者: StephenW    时间: 2019-10-30 17:20

Aligos Therapeutics将在The LiverMeeting®2019期间展示多张海报
张贴海报,重点介绍公司用于HBV和NASH的开发阶段产品的最新进展

2019年10月29日,加利福尼亚州南旧金山-全球领先的临床前生物技术公司Aligos Therapeutics,Inc.(Aligos)致力于开发针对肝病和病毒感染(包括慢性)的靶向疗法乙型肝炎(CHB),非酒精性脂肪性肝炎(NASH)和肝细胞癌(HCC)今天宣布,即将在美国肝脏病研究协会(AASLD)每年主办的The LiverMeeting®上发表四篇摘要。 2019年会议将于11月8日至12日在波士顿举行。

Aligos的科学家团队的专家将展示海报,详细介绍该公司正在开发的产品的最新进展,以应对CHB和NASH。海报展示的详细信息包括以下内容:

海报会议I
日期/时间:11月8日,星期五,下午12:30 –下午1:30 ET
地点:约翰·海因斯纪念会议中心

    海报标题:抑制S抗原转运的寡核苷酸聚合物(STOPs)可有效抑制乙型肝炎病毒(HBV)细胞系分泌的乙型肝炎表面抗原(HBsAg)
    海报编号:689
    演讲人:金宏(寡核苷酸生物学主任)

    海报标题:新型衣壳装配调节剂ALG-001075的临床前评估证明其具有一流的体外效价和体内抗病毒功效
    海报编号:699
    演讲人:Yannick Debing(高级科学家)

    海报标题:新型II类衣壳装配调节器ALG-001024的效能和功效的临床前评估
    海报编号:703
    演讲人:Andreas Jekle(病毒学总监)

海报会议IV
日期/时间:11月11日,星期一,下午12:30 –下午1:30 ET
地点:约翰·海因斯纪念会议中心

    海报标题:ALG-009作为一种有效的选择性甲状腺激素受体β激动剂用于NASH治疗的临床前开发
    海报编号:2149
    演讲人:Jerome Deval(生物化学总监)

关于阿里戈斯
Aligos Therapeutics,Inc.是一家私有生物技术公司,成立于2018年,其使命是成为肝脏疾病治疗的全球领导者。 Aligos专注于针对肝病和病毒感染的靶向疗法的开发,包括慢性乙型肝炎(CHB),非酒精性脂肪性肝炎(NASH)和肝细胞癌(HCC),这些疾病共同影响着全球成千上万人。 Aligos的策略是利用其在肝脏疾病(尤其是病毒性肝炎)方面的专业知识和数十年的药物开发经验,以快速推进其同类最佳分子的生产。
请访问www.aligos.com了解更多信息。




欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) Powered by Discuz! X1.5